<DOC>
	<DOCNO>NCT00094328</DOCNO>
	<brief_summary>The primary objective study investigate whether bicalutamide give combination anastrozole daily 12 month effective treat testotoxicosis boy . Testotoxicosis condition cause early puberty boy include growth height , development muscle sexual organ .</brief_summary>
	<brief_title>Pediatrics Testotoxicosis Study Bicalutamide Anastrozole Treatment Testotoxicosis</brief_title>
	<detailed_description />
	<mesh_term>Puberty , Precocious</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Provision write informed consent parent/legal guardian subject assent ( need local requirement ) Male age 2 year Diagnosis testotoxicosis base following : Clinical feature Progressive sexual precocity document Tanner stag evidence symmetrical testicular enlargement Clinical feature significantly advanced bone age ( define bone age least 12 month beyond chronological age ) Pubertal level serum testosterone Prepubertal level serum gonadotropin Lack increase serum gonadotropin level follow GnRH stimulation Other pathology exclude : Undetectable plasma b human chorionic gonadotropin ( bHCG ) . Samples value LOQ report `` &lt; 10 IU/L '' clinical set equate 'undetectable ' . Normal level 17hydroxyprogesterone ( 17OHP ) Normal level dehydroepiandrosterone sulphate ( DHEAS ) Naive anti androgen receptor therapy : ( Note : Ketoconazole Spironolactone consider acceptable prior use anastrozole aromatase inhibitor ) A document reliable height measurement take &gt; 6 month prior study enrollment . Additionally subject previously receive ketoconazole spironolactone treatment , document reliable height measurement take immediately prior begin treatment . ( Note : subject receive previous treatment single assessment need take immediately prior begin treatment &gt; 6 month prior study entry ) Subjects free endocrine effect previous treatment testotoxicosis prior study entry : ensure 15 day 4 drug half life ( whichever longer ) washout period prior medication testotoxicosis . Evidence central precocious puberty demonstrate GnRH stimulation test Serum concentration total direct bilirubin , GGT , AST ALT great 1.5 time upper limit normal age Serum concentration creatinine great 1.5 time upper limit normal age Any concomitant medical condition , opinion investigator , may expose subject unacceptable level safety risk affect subject compliance Known hypersensitivity study medication Participation clinical study time enrollment</criteria>
	<gender>Male</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Testotoxicosis</keyword>
	<keyword>Familial Male-limited Precocious Puberty ( FMPP )</keyword>
</DOC>